Lundbeck bets on four core products during hard year

While Northera sales plummeted more rapidly than expected, Lundbeck plans for its other products to make up for this loss, especially now that the migraine drug Vyepti is gaining momentum.

Lundbeck CFO Anders Götzsche. | Photo: BUNDGAARD CARSTEN/ERH

On Tuesday, Lundbeck brought a pleasant surprise to the market by presenting its report for Q1 which was better than anticipated, both in terms of the bottom line and the top line.

The company advanced in spite of the fact that the expiration of the patent for the drug Northera hit the company harder than expected, and it seems this development will carry on.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs